Riik: Iisrael
keel: inglise
Allikas: Ministry of Health
CEFUROXIME AS SODIUM
A.L. MEDI-MARKET LTD.
J01DC02
POWDER FOR SOLUTION FOR INJ/INF
CEFUROXIME AS SODIUM 750 MG/VIAL
I.M, I.V
Required
MEDOCHEMIE LTD (FACTORY C), CYPRUS
CEFUROXIME
Cefuroxime Medo is indicated for the treatment of the infections listed below in adults and children, including neonates (from birth)• Community acquired pneumonia• Acute exacerbations of chronic bronchitis• Complicated urinary tract infections, including pyelonephritis• Soft-tissue infections: cellulitis, erysipelas and wound infections• Intra-abdominal infections • Prophylaxis against infection in gastrointestinal (including oesophageal), orthopaedic, cardiovascular, and gynaecological surgery (including caesarean section) • nose infections for example, sinusitis • septic arthritis
2021-10-31
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT CEFUROXIME MEDO 750 MG powder for Solution for Injection or Infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Vials contain 750 mg cefuroxime (as cefuroxime sodium). The total quantity of sodium per vial is 40.65 mg (1.77 mmol). 3. PHARMACEUTICAL FORM Powder for solution for injection or infusion. White or almost white to yellowish powder. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Cefuroxime Medo 750 mg is indicated for the treatment of the infections listed below in adults and children, including neonates (from birth) (see sections 4.4 and 5.1). Community acquired pneumonia Acute exacerbations of chronic bronchitis Complicated urinary tract infections, including pyelonephritis Soft-tissue infections: cellulitis, erysipelas and wound infections Intra-abdominal infections (see section 4.4) Prophylaxis against infection in gastrointestinal (including oesophageal), orthopaedic, cardiovascular, and gynaecological surgery (including caesarean section) Nose infections for example, sinusitis Septic arthritis In the treatment and prevention of infections in which it is very likely that anaerobic organisms will be encountered, cefuroxime should be administered with additional appropriate antibacterial agents. Consideration should be given to official guidance on the appropriate use of antibacterial agents. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Table 1. Adults and children _ _40 kg _ _ _ INDICATION DOSAGE Community acquired pneumonia and acute exacerbations of chronic bronchitis _ _ _ _ 750 mg every 8 hours (intravenously or intramuscularly) Soft-tissue infections: cellulitis, erysipelas and wound infections. Intra-abdominal infections Sinusitis, septic arthritis 750 mg every 8 hours (intravenously or intramuscularly). For more severe infections, this dose should be increased to 1.5g every 8 hours i.v. The frequency of i.m. or i.v. injections can be increased to six-hourly if necessary, giving Lugege kogu dokumenti